Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

Míreanna comhchosúla

• Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
  de réir: William Hinton, et al.
  Foilsithe / Cruthaithe: (2021-06-01)
• Does renal function or heart failure diagnosis affect primary care prescribing for sodium-Glucose co-transporter 2 inhibitors in type 2 diabetes?
  de réir: Hinton, W, et al.
  Foilsithe / Cruthaithe: (2020)
• Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
  de réir: Hinton, W, et al.
  Foilsithe / Cruthaithe: (2020)
• How generalizable are cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors? A national database study: study protocol
  de réir: Hinton, W, et al.
  Foilsithe / Cruthaithe: (2019)
• Disparities in prescribing of sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP-4 inhibitors in people with Type 2 diabetes and chronic kidney disease (CKD)
  de réir: Shah, S, et al.
  Foilsithe / Cruthaithe: (2018)